THL Credit, Inc. TCRX 深 滬
已收盤 07-18 16:00:00 美东时间
1.82
-0.070
-3.70%
華盛通- 最 高1.91
- 今 開1.90
- 成交量 17.84万股
- 最 低 1.81
- 昨 收 1.89
- 總市值 1.03亿
- 52周最高 7.31
- 市盈率 靜 --
- 換手率 0.32%
- 52周最低 1.02
- 委 比 26.59%
- 總股本 5659.06万
- 歷史最高 14.71
- 量 比 0.60
- 振 幅 5.29%
- 歷史最低 1.02
- 每 手 1
- 風險率 1.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
TScan Therapeutics, Inc. will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 4:55 p.m. ET in New York. A webcast will be available on the company’s website, ir.tscan.com, with an archived replay for 90 days. TScan is a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment. The company is currently enrolling patients in two clinical programs: ALLOHA™ for hematologic malignancies a...
05-28 11:00
美股大行评级 | 潜在涨幅105.34%！Amylyx Pharmaceuticals获Leerink Partners升目标价至10美元，上调至"跑赢大市"评级
每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。
05-08 08:45
HC Wainwright & Co. Maintains Buy on TScan Therapeutics, Lowers Price Target to $10
HC Wainwright & Co. analyst Andres Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $15 to $10.
05-07 20:26
TScan Therapeutics GAAP EPS of $0.26
TScan Therapeutics press release (NASDAQ:TCRX): Q1 GAAP EPS of $0.26. Revenue of $2.2M beats by $1.12M. More on TScan Therapeutics TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025 TScan Ther...
05-06 23:13
美股大行评级 | 潜在涨幅147.43%！HC Wainwright & Co.上调Pacira BioSciences目标价至65美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1116650478822592513.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Pacira BioSciences(PCRX)"买入"评级，目标价从48美元升至65美元</p> <p>• 瑞穗：上调Amylyx Pharmaceuticals(AM
04-09 08:50
Needham Reiterates Buy on TScan Therapeutics, Maintains $9 Price Target
Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $9 price target.
04-08 20:46
美股大行评级 | 美银证券：维持AerCap Holdings"买入"评级，目标价从105美元升至125美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1105190809351499777.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• RBC Capital：维持Canadian Natural Res(CNQ)"跑赢大市"评级，目标价从62美元升至63美元</p> <p>• 摩根大通：维持Carvana(CVNA)"超配"评级，目标价从350美元升至3
03-10 10:29
美股大行评级 | 摩根大通：维持Alignment Healthcare"中性"评级，目标价从14美元升至17美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1104689832132448256.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Chardan Capital：维持Ocugen(OCGN)"买入"评级，目标价从6美元升至7美元</p> <p>• Piper Sandler：维持ALX Oncology Holdings(ALXO)"超配"评级，目标
03-07 13:53
美股大行评级 | 富国银行：维持艾伯维"超配"评级，目标价从210美元升至240美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1104327819967434752.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Syndax制药(SNDX)"超配"评级，目标价从35美元升至39美元</p> <p>• 摩根大通：维持AnaptysBio(ANAB)"超配"评级，目标价从36美元升至42美元</p> <p>• 摩根大通
03-06 11:20
TScan Therapeutics files for $300M mixed securities shelf
TScan Therapeutics (NASDAQ:TCRX) filed for $300M mixed securities shelf. This prospectus is not an offer to sell. Filing More on TScan Therapeutics TScan Therapeutics: Finding Their Footing After An E...
03-06 05:34
